Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 3,000 Shares

Posted by Stanley Muller on May 19th, 2026

Gilead Sciences logo Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Stock Up 0.1%

GILD stock opened at $129.67 on Tuesday. The company has a market cap of $160.99 billion, a PE ratio of 17.67 and a beta of 0.31. The business has a 50-day simple moving average of $137.46 and a 200 day simple moving average of $133.40. Gilead Sciences, Inc. has a 52 week low of $102.84 and a 52 week high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.78 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s payout ratio is presently 44.69%.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences during the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC boosted its holdings in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares during the last quarter. Quattro Advisors LLC bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $26,000. Wealth Preservation Advisors LLC boosted its holdings in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $28,000. 83.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

GILD has been the subject of several research analyst reports. Bank of America set a $162.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Wall Street Zen downgraded Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. The Goldman Sachs Group boosted their target price on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Morgan Stanley lowered their target price on Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Finally, Royal Bank Of Canada lowered their target price on Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating for the company in a research note on Friday, May 8th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $157.04.

Read Our Latest Research Report on GILD

Gilead Sciences Company Profile

(Get Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.